Clinical ReadoutsRoche will deliver a substantial number of clinical readouts, which can decide a turnaround to the story.
Price Target IncreaseStock’s price target is increasing by 11% to CHF340 due to upgrades and peer group multiple expansion.
Sales ForecastThree potential assets, each forecasted to generate over $5bn in sales, have been highlighted, with Giredestrant for 1L breast cancer showing the highest conviction.